

Neoplasias Tímicas

Dr. Ignacio Gil-Bazo


Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

- **Role of Post-Operative Radiation in Different Histologic Subgroups of Thymoma: Result Based on National Cancer Data Base (NCDB)**

- **PORT patients were:**
 - Younger
 - Had insurance
 - More A, A/B histology
 - More positive margins
 - Residual tumor
 - 7.4% vs. **14.9%**
 - Microscopic residual tumor
 - 9.2% vs. **25%**



- **Role of Post-Operative Radiation in Different Histologic Subgroups of Thymoma: Result Based on National Cancer Data Base (NCDB)**

- PORT was associated with improved survival
 - Type A, AB, B3; Not for B1, B2
 - No evidence of detrimental OS from PORT
- OS multivariable analysis
 - Age >60, Race, Co-morbidity, margins, and PORT
 - No histology in the MVA

Estudio poblacional de incidencia y supervivencia de neoplasias tímicas

- A Population-Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies: Results from the California Cancer Registry

Results: characteristics of study population between 1988 and 2015

<u>Gender</u>	<u>N</u>	<u>%</u>
Male	918	57.8%
Female	670	42.2%
Total	1,588	100.0%

<u>Socioeconomic Status</u>	<u>N</u>	<u>%</u>
Lowest	191	12.0%
Lower-Middle	245	15.4%
Middle	343	21.6%
Upper-Middle	333	21.0%
Highest	425	26.8%
Unknown	51	3.2



<u>Year of Diagnosis</u>	<u>N</u>	<u>%</u>
1988-1994	247	15.6%
1995-2001	341	21.5%
2002-2008	451	28.4%
2009-2015	549	34.6%

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

Estudio poblacional de incidencia y supervivencia de neoplasias tímicas




Iniciativa científica de:





Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

Expresión comparativa de PD-L1 en Carcinoma Tímico

- A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma



Expresión comparativa de PD-L1 en Carcinoma Tímico




Iniciativa científica de:




Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

- Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)



- Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)



Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

KOSMIC: Sunitinib en Carcinoma Tímico pretratado

